🔴 Harmony Biosciences is trading 6.4% down in pre-market — catalyst remains unclear

Harmony Biosciences is trading 6.4% down at $39.50 after no clear company-specific announcement was identified for September 17, 2026.

• Recent company communications highlighted EPX-100 presentations, while the latest available filing search showed no new major filing or 8-K explaining the decline.
• The broader market is firmer in pre-market trading, with major indexes higher, so the decline does not appear to track overall risk sentiment.
• The catalyst remains unclear.